Gilead Sciences
The goal of this clinical study is to learn more about the study drugs lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) to assess how it is absorbed, modified, distributed and eliminated from the body of young people (the pharmacokinetics (PK) parameters of the drugs). It will also check the safety, and tolerability of LEN in combination with TAB, and ZAB in participants living with human immunodeficiency virus type 1 (HIV-1). The primary objectives of this study are to evaluate the PK parameters, safety, and tolerability of LEN, TAB, and ZAB.
Key Inclusion Criteria: * Individuals must be aged ≥ 12 to \< 18 years at Screening Visit 1 (SV1) and enrollment (Day 1). * Weight ≥ 35 kg at Day 1. * On a stable oral antiretroviral (ARV) regimen for at least 6 months prior to SV1. * At least 1 documented HIV-1 RNA level measured between 6 months and 12 months (+ 2 months) prior to SV1. This and any other HIV-1 RNA measurements documented in this period must be \< 50 copies/mL (undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL). * A plasma HIV-1 RNA test \< 50 copies/mL (undetect…
Administered orally
Administered SC
Administered IV
Administered IV
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.